Crossmark

The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial

Crossref DOI link: https://doi.org/10.1007/s10198-026-01981-w

Published Online: 2026-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Kun https://orcid.org/0000-0003-1587-3325
Sweeting, Michael

Wilking, Nils

Jönsson, Linus
Funding

Funding for this research was provided by:

Karolinska Institute
License Information

Text and Data Mining valid from 2026-08-21

Version of Record valid from 2026-08-21
More Information

Article History

Received: 28 March 2026

Accepted: 5 August 2026

First Online: 21 August 2026

Declarations

Ethics approval: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below